Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.32 |
| ▸ | PTPN22 | Q9Y2R2 | 4/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 5/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | PTPN12 | Q05209 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | DUSP6 | Q16828 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87206 | 0.90 | HSD17B10 (0.31) | L3MBTL1HPGDATMKMT2ATP53 | |
| SCHEMBL51931 | 0.87 | HPGD (0.40) | L3MBTL1HPGDMEN1KMT2APTPN22 | |
| SCHEMBL87253 | 0.82 | MMP9 (0.31) | — | |
| SCHEMBL13691675 | 0.82 | MEN1 (0.31) | L3MBTL1HPGDATMMEN1KMT2A | |
| SCHEMBL53152 | 0.80 | HPGD (0.38) | L3MBTL1HPGDMEN1KMT2APOLB | |
| SCHEMBL52083 | 0.80 | HPGD (0.38) | L3MBTL1HPGDMEN1KMT2APOLB | |
| SCHEMBL16130200 | 0.77 | TLR2 (0.38) | L3MBTL1HPGDATMPOLBTP53 | |
| SCHEMBL51826 | 0.77 | OGFRL1 (0.35) | L3MBTL1HPGDMEN1KMT2ABLM | |
| SCHEMBL62833 | 0.76 | MAOB (0.33) | L3MBTL1HPGDMEN1KMT2APOLB | |
| SCHEMBL52189 | 0.75 | OGFRL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | L3MBTL1 2276/4885HPGD 1406/4885ATM 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.